FindTrial
Sign In

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06546059
Enrollment
40
Registered
2024-08-09
Start date
2024-08-31
Completion date
2024-11-30
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo, Generalized

Brief summary

The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Detailed description

The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Interventions

DEVICEnarrow band ultraviolet-B

vitiligo patients will recevie twice sessions per week

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with stable vitiligo of 6 months duration, * Both sex and ages(10-75)

Exclusion criteria

* pregnancy, * lactation, * patients under or previous phototherapy, * patients on other immunosuppressives, * patients receiving topical or systemic therapy like antioxidants and vitamins were kept off treatment for 2 weeks prior to recruitment into the study.

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.three months1- Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.techniques in patients with generalized vitiligo and compare it with healthy controls.

Secondary

MeasureTime frameDescription
2- Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy.three months2- Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy.
3- Determine whether there is a correlation between tissue immunehistochemstry Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.three months3- Determine whether there is a correlation between tissue immunehistochemstry D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Contacts

Primary ContactSoheir Abdel-Hamid, MD
soher.abdel-hamid@med.svu.edu.eg01066877343
Backup ContactBasma Tito Abd Elhameed, MD
Basma.tito@med.svu.edu.eg01020304210

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026